Our pipeline currently centers on two promising compounds developed by world renowned Professors’ Chang and Han.
This platform drug as shown promise for the treatment of Acute Myeloid Leukemia. Formally known as TPA, this platform small molecule has many potential therapeutic uses. Rich Pharmaceuticals is exploring multiple indications for the highest likelihood of commercialization success that has the potential to become new compelling treatments for patients.
Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson’s Disease: Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials
Rich Pharmaceuticals Announces Institutional Review Board Submission